Public market insider buying at Eupraxia Pharmaceuticals (EPRX)

Public market insider buying at Eupraxia Pharmaceuticals (T:EPRX)

Michael Wilmink, a Director, acquired 44,444 Common Shares on a direct ownership basis at a price of $2.160USD between September 14th, 2021 and September 15th, 2021. This represents a $121,540 investment into the company's shares and an account share holdings change of 68.4%.

Eupraxia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company with a drug delivery technology platform. The Company's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The Company's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The Company is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The Company is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.